WindMIL Therapeutics
Anna French, PhD, is a partner at Qiming Venture Partners, based in Boston. Prior to joining Qiming Ventures in July 2017, Dr. French was a management consultant at the Boston Consulting Group (BCG) where she advised top 10 global biopharma companies on their strategy and operations. Prior to BCG, Dr. French led a global industry-academic consortium focused on cell therapy commercialization.
Dr. French earned a PhD (D.Phil) from the University of Oxford, UK in Clinical Laboratory Sciences where her research focused on hematological applications of human induced pluripotent stem (iPS) cells. She has a 1st Class BSc. in Biochemistry from the University of Bristol, UK.
Dr. French has over 20 publications in the field of stem cell research, including in Cell Stem Cell, Nature Biotechnology and Trends in Biotechnology. She is an editorial board member for Current Stem Cell Research & Therapy and an invited reviewer for a number of journals.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
WindMIL Therapeutics
WindMIL Therapeutics is a clinical stage oncology cell therapy company. The company is leveraging its proprietary platform to develop a novel class of cell therapies called MILs™ (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.